2012 has been an exciting year for kidney cancer research. From the FDA approval of a new targeted agent to revival of interest in immunotherapy, several interesting studies were published that generated considerable interest.
This is a preview of subscription content, log in via an institution to check access.
References
Rini, B. I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378, 1931–1939 (2011).
Motzer, R. J. et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J. Clin. Oncol. 30, 1371–1377 (2012).
Houk, B. E. et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol. 66, 357–371 (2010).
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B. Rini declares consulting and research funding from Pfizer. K. Mittal declares no competing interests.
Rights and permissions
About this article
Cite this article
Mittal, K., Rini, B. New frontiers in kidney cancer research. Nat Rev Urol 10, 70–72 (2013). https://doi.org/10.1038/nrurol.2012.256
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2012.256
- Springer Nature Limited